Short Interest in Pyxis Oncology, Inc. (NASDAQ:PYXS) Drops By 14.7%

Pyxis Oncology, Inc. (NASDAQ:PYXS) was the target of a significant drop in short interest during the month of April. As of April 15th, there was short interest totaling 2,269,065 shares, a drop of 14.7% from the March 31st total of 2,660,931 shares. Currently, 4.0% of the company’s shares are sold short. Based on an average daily volume of 402,636 shares, the short-interest ratio is presently 5.6 days.

Hedge Funds Weigh In On Pyxis Oncology

Several institutional investors have recently bought and sold shares of the business. Laurion Capital Management LP increased its holdings in Pyxis Oncology by 32.3% during the fourth quarter. Laurion Capital Management LP now owns 4,796,479 shares of the company’s stock valued at $5,516,000 after buying an additional 1,170,505 shares during the period. Vanguard Group Inc. increased its holdings in Pyxis Oncology by 0.7% during the third quarter. Vanguard Group Inc. now owns 2,163,962 shares of the company’s stock valued at $4,804,000 after buying an additional 14,566 shares during the period. 683 Capital Management LLC increased its holdings in Pyxis Oncology by 69.9% during the fourth quarter. 683 Capital Management LLC now owns 891,910 shares of the company’s stock valued at $1,026,000 after buying an additional 366,910 shares during the period. Jane Street Group LLC increased its holdings in Pyxis Oncology by 158.8% during the fourth quarter. Jane Street Group LLC now owns 786,010 shares of the company’s stock valued at $904,000 after buying an additional 482,310 shares during the period. Finally, Renaissance Technologies LLC increased its holdings in Pyxis Oncology by 26.4% during the fourth quarter. Renaissance Technologies LLC now owns 728,380 shares of the company’s stock valued at $838,000 after buying an additional 152,044 shares during the period. 39.07% of the stock is owned by hedge funds and other institutional investors.

Pyxis Oncology Stock Up 1.2%

PYXS stock traded up $0.02 during trading on Friday, hitting $1.72. 102,324 shares of the company’s stock traded hands, compared to its average volume of 607,646. The firm has a market capitalization of $108.07 million, a P/E ratio of -1.33 and a beta of 1.41. The business has a fifty day simple moving average of $1.55 and a two-hundred day simple moving average of $2.38. Pyxis Oncology has a 1 year low of $0.97 and a 1 year high of $5.55.

Pyxis Oncology (NASDAQ:PYXS) last issued its quarterly earnings data on Monday, March 23rd. The company reported ($0.29) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.35) by $0.06. The business had revenue of $11.04 million for the quarter, compared to analysts’ expectations of $0.13 million. On average, equities research analysts predict that Pyxis Oncology will post -1.24 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities analysts have recently commented on the stock. HC Wainwright reaffirmed a “buy” rating and set a $7.00 target price on shares of Pyxis Oncology in a research report on Tuesday, March 24th. Stifel Nicolaus lowered their price target on Pyxis Oncology from $9.00 to $8.00 and set a “buy” rating for the company in a report on Tuesday, March 24th. Wall Street Zen upgraded Pyxis Oncology from a “sell” rating to a “hold” rating in a report on Monday, April 13th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Pyxis Oncology in a report on Thursday, January 22nd. Five analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Pyxis Oncology presently has a consensus rating of “Moderate Buy” and a consensus price target of $7.00.

Pyxis Oncology Company Profile

Pyxis Oncology (NASDAQ: PYXS) is a clinical?stage biotechnology company focused on the discovery and development of targeted oncology therapies. The company’s platform centers on antibody?drug conjugates (ADCs) that deliver potent mitotic inhibitors directly to cancer cells, leveraging novel payloads designed to disrupt cell division. By combining highly specific antibodies with innovative cytotoxic agents, Pyxis Oncology aims to improve therapeutic windows and reduce off?target toxicities common to conventional chemotherapies.

Since its inception, Pyxis Oncology has built a pipeline of early?stage ADC candidates directed against a variety of solid tumor antigens.